Literature DB >> 17982502

Recent improvement in outcome of unrelated donor transplantation for aplastic anemia.

R Viollier1, G Socié, A Tichelli, A Bacigalupo, E T Korthof, J Marsh, J Cornish, P Ljungman, R Oneto, A N Békássy, M Fuehrer, S Maury, H Schrezenmeier, M T van Lint, D Wojcik, A Locasciulli, J R Passweg.   

Abstract

The aim was to determine whether outcome of unrelated donor transplantation for severe aplastic anemia has improved in recent years and whether this is due to patient selection or better transplant technology. We analyzed 498 patients transplanted during 1990-2005. By running univariate regression models dichotomizing year of transplantation we defined 1998 as the year of the most significant change in survival. Five-year survival increased from 32+/-8% before 1998 to 57+/-8% after 1998 (P<0.0001). When comparing the cohort before (n=149) and after 1998 (n=349), there were no differences except for older age, and more frequent use of PBSCs, after 1998. High-resolution HLA typing data were unavailable. After 1998, there was less graft failure (11 vs 26%, P<0.0001), less acute GvHD (cumulative incidence 28 vs 37%, P=0.02) and less chronic GvHD (22 vs 38%, P=0.004). In multivariate analyses adjusting for differences in age, HLA-mismatch, performance score and time to transplantation, there was no change in the year of transplant effect (relative risk of death in transplants after 1998: 0.44 (95% confidence interval 0.33-0.59)). There is no evidence for patient selection to explain significantly improved survival in patients transplanted after 1998. We speculate that this is due to better donor matching.

Entities:  

Mesh:

Year:  2007        PMID: 17982502     DOI: 10.1038/sj.bmt.1705894

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  31 in total

Review 1.  How I treat acquired aplastic anemia.

Authors:  Phillip Scheinberg; Neal S Young
Journal:  Blood       Date:  2012-04-19       Impact factor: 22.113

2.  Mechanisms of alloimmunization and subsequent bone marrow transplantation rejection induced by platelet transfusion in a murine model.

Authors:  S R Patel; N H Smith; L Kapp; J C Zimring
Journal:  Am J Transplant       Date:  2012-02-02       Impact factor: 8.086

3.  Allogeneic hematopoietic cell transplantation for severe aplastic anemia: similar long-term overall survival after transplantation with related donors compared to unrelated donors.

Authors:  B K Mortensen; N Jacobsen; C Heilmann; H Sengeløv
Journal:  Bone Marrow Transplant       Date:  2015-10-05       Impact factor: 5.483

4.  Paroxysmal nocturnal hemoglobinuria and telomere length predicts response to immunosuppressive therapy in pediatric aplastic anemia.

Authors:  Atsushi Narita; Hideki Muramatsu; Yuko Sekiya; Yusuke Okuno; Hirotoshi Sakaguchi; Nobuhiro Nishio; Nao Yoshida; Xinan Wang; Yinyan Xu; Nozomu Kawashima; Sayoko Doisaki; Asahito Hama; Yoshiyuki Takahashi; Kazuko Kudo; Hiroshi Moritake; Masao Kobayashi; Ryoji Kobayashi; Etsuro Ito; Hiromasa Yabe; Shouichi Ohga; Akira Ohara; Seiji Kojima
Journal:  Haematologica       Date:  2015-08-27       Impact factor: 9.941

Review 5.  Alternative donor transplants for severe aplastic anemia.

Authors:  Andrea Bacigalupo
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 6.  Alternative donor transplant of benign primary hematologic disorders.

Authors:  J Tolar; P Sodani; H Symons
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

7.  Association between donor leukocyte telomere length and survival after unrelated allogeneic hematopoietic cell transplantation for severe aplastic anemia.

Authors:  Shahinaz M Gadalla; Tao Wang; Michael Haagenson; Stephen R Spellman; Stephanie J Lee; Kirsten M Williams; Jason Y Wong; Immaculata De Vivo; Sharon A Savage
Journal:  JAMA       Date:  2015-02-10       Impact factor: 56.272

Review 8.  Clinical management of aplastic anemia.

Authors:  Amy E Dezern; Robert A Brodsky
Journal:  Expert Rev Hematol       Date:  2011-04       Impact factor: 2.929

9.  Minor antigens on transfused RBCs crossprime CD8 T cells but do not induce full effector function.

Authors:  M Desmarets; G Mylvaganam; E K Waller; C D Josephson; C Pack; A E Lukacher; J C Zimring
Journal:  Am J Transplant       Date:  2011-09       Impact factor: 8.086

Review 10.  Transfusion-induced bone marrow transplant rejection due to minor histocompatibility antigens.

Authors:  Seema R Patel; James C Zimring
Journal:  Transfus Med Rev       Date:  2013-10-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.